VIP943
An Open-label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of VIP943 Monotherapy in Subjects With Advanced CD123+ Hematologic Malignancies
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 36 patients (estimated)
- Sponsors
- Vincerx Pharma, Inc.
- Tags
- Antibody Drug Conjugate (ADC), Kinesin Spindle Protein (KSP) Inhibitor, CD123
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1769
- NCT Identifier
- NCT06034275
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.